Subtype
Urothelial Neoplasm
CI-CAN-00001629Explore in graph →
Non-malignant236 active trials5 approved drugs8 evidence items
- NCIt
- C39852
Loading cancer entity…
Subtype
CI-CAN-00001629Explore in graph →
Clinical trials
625 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00942331 | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer | completed | Phase 3 | 506 | National Cancer Institute (NCI)NIH | 2 | Jun 24, 2026 | clinicaltrials |
| NCT03898180 | Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) | completed | Phase 3 | 505 | Merck Sharp & Dohme LLCINDUSTRY |
| 20 |
| Feb 5, 2026 |
| clinicaltrials |
| NCT02807636 | Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma(IMvigor130) | completed | Phase 3 | 1,213 | Hoffmann-La RocheINDUSTRY | 35 | Feb 24, 2025 | clinicaltrials |
| NCT05136898 | Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) | completed | Phase 3 | 8 | UroGen Pharma Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02426125 | A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer(RANGE) | completed | Phase 3 | 530 | Eli Lilly and CompanyINDUSTRY | 23 | Aug 21, 2023 | clinicaltrials |
| NCT02818725 | I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations(GETUG-AFU19) | completed | Phase 3 | 133 | UNICANCEROTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT02793128 | The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study(Olympus) | completed | Phase 3 | 71 | UroGen Pharma Ltd.INDUSTRY | 2 | Dec 22, 2020 | clinicaltrials |
| NCT00315237 | Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract | completed | Phase 3 | 364 | Pierre Fabre MedicamentINDUSTRY | 1 | Jan 7, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Jun 24, 2026source: clinicaltrials